On Mar. 8, 2018, Sanofi acquired Waltham, Massachusetts-based Bioverativ for for $11.6 billion. Bioverativ’s extended half-life therapies, Eloctate Antihemophilic Factor VIII (Recombinant), Fc Fusion Protein and Alprolix Coagulation Factor IX (Recombinant), Fc Fusion Protein for the treatment of hemophilia A and B, respectively, represented the first major advancements in the hemophilia market in nearly two decades when launched.

In 2016, Bioverativ generated $847 million in sales and $41 million in royalties.